METHOD FOR LABORATORY DIAGNOSIS OF COVID-19 SEVERITY BY DETERMINING THE RATIO OF VON WILLEBRAND FACTOR AND ADAMTS-13 ACTIVITY Russian patent published in 2022 - IPC G01N33/68 G01N33/86 C12Q1/37 C12Q1/56 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to clinical laboratory diagnostics, and can be used for laboratory diagnostics of the severity of COVID-19. The determination of the von Willebrand factor in the blood is performed. In a patient with a laboratory-confirmed diagnosis of COVID-19, when determining the von Willebrand factor in blood plasma, its ristocytin-cofactor activity is assessed and, additionally, the activity of ADAMTS-13 is determined. The ratio of von Willebrand factor activity to ADAMTS-13 is then calculated. If the ratio is less than 1.55, the patient is diagnosed with a mild severity of COVID-19. If the ratio is more than 1.55, the patient is diagnosed with a moderate or severe degree of COVID-19.

EFFECT: method enables highly sensitive and highly specific laboratory diagnostics, which makes it possible to predict the severity of COVID-19 with high accuracy, by determining the ratio of ristocytin-cofactor activity of von Willebrand factor and ADAMTS-13 activity in the patient's blood.

1 cl, 3 ex